Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment
Rhea-AI Filing Summary
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported a small acquisition of 34.0000 shares of common stock on 2026-07-22 at 206.8070 per share through a broker-administered dividend reinvestment plan, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was reported early. Following this transaction, his direct holdings total 11935.0000 shares. A footnote notes that the security is described as common stock but represents an award of restricted share units.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 34 shares
Net Buy
1 txn
Insider
DELANEY MARK E
Role
SVP & Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock F1, F2 | 34 | $206.807 | $7K |
Holdings After Transaction:
Common Stock — 11,935 shares (Direct)
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 34.0000 shares
Price per share: 206.8070
Direct holdings after transaction: 11935.0000 shares
3 metrics
Shares acquired
34.0000 shares
Non-derivative common stock acquisition on 2026-07-22
Price per share
206.8070
Acquisition price per share for the 34.0000-share transaction
Direct holdings after transaction
11935.0000 shares
Mark E. Delaney’s direct ownership following the reported acquisition
Key Terms
restricted share units, dividend reinvestment plan, Rule 16a-6
3 terms
dividend reinvestment plan financial
"shares that were acquired pursuant to a dividend reinvestment plan administered"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Quest Diagnostics (DGX) report in this Form 4?
Quest Diagnostics reported that SVP & Chief Commercial Officer Mark E. Delaney acquired 34.0000 shares of common stock on 2026-07-22 at 206.8070 per share. The acquisition was reported as a small transaction under Rule 16a-6, increasing his direct holdings to 11935.0000 shares.
What are Mark E. Delaney’s Quest Diagnostics (DGX) holdings after this Form 4 transaction?
After acquiring 34.0000 shares, Mark E. Delaney directly holds 11935.0000 shares of Quest Diagnostics common stock. This total reflects his direct ownership position following the dividend reinvestment plan transaction reported as a small acquisition under Rule 16a-6 on 2026-07-22.
Was the Quest Diagnostics (DGX) insider transaction deferred under Rule 16a-6?
The shares were eligible for deferred reporting on Form 5 under Rule 16a-6, because they arose from a dividend reinvestment plan. However, the reporting person chose to report the 34.0000-share acquisition early on Form 4 instead of waiting to use Form 5.